Analysis of Efficacy and Safety of Neoadjuvant Immunochemotherapy in Patients
with Stage IB-IIIB Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2025.106.16
- Author:
Zihao LI
1
;
Xin WANG
1
;
Yulong WANG
1
;
Zhuoer CUI
1
;
Xin WANG
2
;
Xiao LI
1
;
Guanchao JIANG
1
;
Xun WANG
1
Author Information
1. Department of Thoracic Surgery, China Thoracic Oncology Institute, Peking University People's Hospital, Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer, Chinese Academy of Medical Sciences, Beijing 100044, China.
2. Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin 300222, China.
- Publication Type:Journal Article
- Keywords:
Immunotherapy;
Lung neoplasms;
Neoadjuvant therapy;
Non-small cell lung cancer
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/mortality*;
Male;
Lung Neoplasms/mortality*;
Female;
Middle Aged;
Neoadjuvant Therapy/adverse effects*;
Aged;
Neoplasm Staging;
Adult;
Immunotherapy/adverse effects*;
Treatment Outcome;
Retrospective Studies
- From:
Chinese Journal of Lung Cancer
2025;28(6):415-426
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Neoadjuvant immunochemotherapy has emerged as an indispensable therapeutic modality for non-small cell lung cancer (NSCLC). However, its clinical application experience remains limited, and the associations between various clinical factors and treatment benefits remain undefined. This study aims to evaluate the efficacy and safety of neoadjuvant immunochemotherapy in patients with stage IB-IIIB NSCLC in a real-world setting, analyze survival outcomes among subgroups with diverse clinical characteristics, and identify potential clinical predictive factors for pathological response.
METHODS:This study included patients with stage IB-IIIB NSCLC who underwent radical lung resection after 2-4 cycles of neoadjuvant immunochemotherapy at Peking University People's Hospital between August 2019 and March 2024. Medical records and follow-up information were collected to analyze therapeutic response, adverse events and survival outcomes. Logistic analysis was used to identify clinical predictors of pathological response.
RESULTS:Among 183 enrolled patients, 116 (63.4%) were stage III. Grade 3-4 immune-related adverse events (irAEs) occurred in 39 (21.3%) patients. Radiographic complete response (CR) or partial response (PR) was achieved in 118 (64.5%) patients. R0 resection was achieved in 180 (98.4%) patients. Major pathologic response (MPR) was observed in 107 (58.5%) patients, with 78 (42.6%) achieving pathologic complete response (pCR). Squamous cell carcinoma and radiographic objective response were associated with pathological response (pCR/MPR). With a median follow-up of 22.1 [interquartile range (IQR): 18.3-32.2] months, the 2-year event-free survival (EFS) and overall survival (OS) rates were 82.5% and 90.4%, respectively. Achievement of pathological response (pCR/MPR) was correlated with prolonged survival outcomes.
CONCLUSIONS:Neoadjuvant immunochemotherapy is safe and effective for patients with stage IB-IIIB NSCLC. Patients achieving pCR or MPR exhibit significantly better survival benefits from neoadjuvant immunochemotherapy. Squamous cell carcinoma and radiographic objective response can serve as clinical predictors of pathological response.
